Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Faron Pharmaceuticals Oy ( (GB:FARN) ) is now available.
Faron Pharmaceuticals Ltd has approved the exercise of 527,948 Special Rights, leading to the issuance of 527,948 new shares for a total subscription price of EUR 986,998.79. These shares have been registered in the Finnish Trade Register and will be traded on First North and AIM around October 6, 2025. The total number of ordinary shares now stands at 117,593,545, with 113,450,867 voting rights available after accounting for treasury shares. This move is expected to impact shareholder calculations regarding their interests in the company.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its mission is to expand the reach of immunotherapy by discovering innovative methods to control and utilize the immune system. The company’s leading product is bexmarilimab, an anti-Clever-1 humanized antibody aimed at reducing cancer immunosuppression by reprogramming myeloid cell function. Bexmarilimab is currently undergoing Phase I/II clinical trials as a potential treatment for hematological cancers in combination with standard therapies.
See more insights into FARN stock on TipRanks’ Stock Analysis page.